Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Beobachtungsstudie zur Bewertung der Flüssigkeitsauflösung und Wirksamkeit bei Patienten, die Beovu bei neovaskulärer altersbedingter Makuladegeneration erhalten (BLUE SKY)

17. November 2026 aktualisiert von: Novartis Pharmaceuticals

BEOBACHTUNGSSTUDIE ZUR BEWERTUNG DER FLÜSSIGKEITSAUFLÖSUNG UND WIRKSAMKEIT BEI PATIENTEN, DIE BEOVU (BROLUCIZUMAB) IM RAHMEN DER SCHLÜSSELBEHANDLUNGSSCHEMAS DER neovaskulären altersbedingten Makuladegeneration erhalten

This study was a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC.

An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS did not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures were only those ordinarily applied to the therapeutic strategy and to routine clinical care and took place as per investigator's discretion. This included e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice was collected as part of the study.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

BLUE SKY consisted of the nAMD-related module BIRL (Brolucizumab In Real Life) and two general, indication-related study modules "BLUE SKY AMD" and "BLUE SKY DME".

Patients were enrolled at 40 centers, which were representatively distributed amongst the 16 German federal states. This should reflect all state-specific health insurance laws and guidelines. Naïve and pre-treated patients were included after decision to start treatment with brolucizumab and consent was given.

All patients were documented either in the AMD or DME-module (Full Analysis Set).

For the BIRL module, only naïve nAMD patients enrolled in 7 selected centers were planned to be documented. All these centers were equipped with the Zeiss PlexElite OCT-A, needed to assess and analyze BIRL specific objectives in a comparable setting. Only images from routine medical practice were collected as part of the study. The study eye was defined as the first eye treated during the study, the other eye was considered as fellow eye. If both eyes were treated at baseline, the eye with the worse VA was chosen as the study eye (if VA was measured equal, the treating ophthalmologist defines the study eye upon his discretion). The prospective observation period per patient was up to 24 months.

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

572

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Aschersleben, Deutschland, 06449
        • Novartis Investigative Site
      • Bayreuth, Deutschland, 95445
        • Novartis Investigative Site
      • Berlin, Deutschland, 10713
        • Novartis Investigative Site
      • Berlin, Deutschland, 14163
        • Novartis Investigative Site
      • Bonn, Deutschland, 53105
        • Novartis Investigative Site
      • Breisach, Deutschland, 79206
        • Novartis Investigative Site
      • Chemnitz, Deutschland, 09113
        • Novartis Investigative Site
      • Cologne, Deutschland, 50968
        • Novartis Investigative Site
      • Dresden, Deutschland, 01067
        • Novartis Investigative Site
      • Dresden, Deutschland, 01324
        • Novartis Investigative Site
      • Esslingen am Neckar, Deutschland, 73728
        • Novartis Investigative Site
      • Glauchau, Deutschland, 08371
        • Novartis Investigative Site
      • Homburg, Deutschland, 66421
        • Novartis Investigative Site
      • Hösbach, Deutschland, 63768
        • Novartis Investigative Site
      • Kiel, Deutschland, 24103
        • Novartis Investigative Site
      • Leipzig, Deutschland, 04106
        • Novartis Investigative Site
      • Magdeburg, Deutschland, 39104
        • Novartis Investigative Site
      • Marienberg, Deutschland, 09496
        • Novartis Investigative Site
      • Münster, Deutschland, 48145
        • Novartis Investigative Site
      • Neubrandenburg, Deutschland, 17036
        • Novartis Investigative Site
      • Schönebeck, Deutschland, 39218
        • Novartis Investigative Site
      • Stralsund, Deutschland, 18435
        • Novartis Investigative Site
      • Sulzbach, Deutschland, 66280
        • Novartis Investigative Site
      • Torgau, Deutschland, 04860
        • Novartis Investigative Site
      • Waren, Deutschland, 17192
        • Novartis Investigative Site
      • Würzburg, Deutschland, 97080
        • Novartis Investigative Site
    • Bavaria
      • Munich, Bavaria, Deutschland, 81377
        • Novartis Investigative Site
      • Neuburg A.d. Donau, Bavaria, Deutschland, 86633
        • Novartis Investigative Site
      • Würzburg, Bavaria, Deutschland, 97080
        • Novartis Investigative Site
      • Würzburg, Bavaria, Deutschland, 97070
        • Novartis Investigative Site
    • Hesse
      • Frankfurt am Main, Hesse, Deutschland, 60590
        • Novartis Investigative Site
    • Lower Saxony
      • Göttingen, Lower Saxony, Deutschland, 37075
        • Novartis Investigative Site
      • Osnabrück, Lower Saxony, Deutschland, 49076
        • Novartis Investigative Site
    • Mecklenburg-Vorpommern
      • Rostock, Mecklenburg-Vorpommern, Deutschland, 18057
        • Novartis Investigative Site
    • Rhineland-Palatinate
      • Trier, Rhineland-Palatinate, Deutschland, 54296
        • Novartis Investigative Site
    • Saarland
      • Saarbrücken, Saarland, Deutschland, 66111
        • Novartis Investigative Site
    • Saxony
      • Dresden, Saxony, Deutschland, 01307
        • Novartis Investigative Site
      • Leipzig, Saxony, Deutschland, 04103
        • Novartis Investigative Site
      • Schneeberg, Saxony, Deutschland, 08289
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Halle, Saxony-Anhalt, Deutschland, 06118
        • Novartis Investigative Site
    • Thuringia
      • Jena, Thuringia, Deutschland, 07740
        • Novartis Investigative Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 99 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Patients being treated for nAMD or DME with brolucizumab were enrolled in the study upon signing an informed consent.

Beschreibung

Inclusion Criteria:

The unit of analysis was patient-eye, i.e. all criteria were applied to the study eye, unless otherwise specified. Patients were included in the study if they fulfilled the following requisites:

  1. Diagnosis of nAMD or visual impairment due to DME
  2. Male and Female nAMD and DME patients with ≥18 years of age at index
  3. Decision to treat with brolucizumab at baseline visit
  4. Signed written informed consent
  5. Patients for whom a therapy with brolucizumab was medically indicated
  6. Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at Screening

Exclusion Criteria:

  1. Patients with any contraindication or who were not eligible for treatment with brolucizumab as according to the SmPC
  2. Patients treated for RVO or CNV other than nAMD
  3. Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index date
  4. Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion (nAMD)
  5. Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date
  6. Patients who have been on anti-VEGF treatment for longer than 3 years (before index date)
  7. Any medical or psychological condition in the treating physician's opinion which may have prevented the patient from the 24 months study participation
  8. Patients participating in parallel in an interventional clinical trial
  9. Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug
  10. Laser photocoagulation (focal/grid or panretinal) in the study eye during the 3-month period prior to baseline
  11. Prior use of intraocular or periocular corticosteroids in the study eye provided at least 4 months prior to baseline
  12. Pregnancy and breast-feeding

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
treatment naïve patients

Patients being the first time treated for nAMD or DME

There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled.

pre-treated patients

Patients already being treated for nAMD or DME

There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of patients' eyes that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF)
Zeitfenster: Month 12

This outcome measure is part of the BLUE SKY AMD module. This primary study objective was addressed considering treatment naïve and pre-treated patient eyes, analyzed as two independent groups (naïve and switch).

Month 12
Mean change in visual acuity (VA) under clinic specific routine treatment schemes
Zeitfenster: Baseline, month 12

This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes.

Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye.

Baseline, month 12
Morphological CNV-Changes under clinic specific routine treatment schemes
Zeitfenster: Baseline, month 12

This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes.

Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye.

Baseline, month 12
Percent of patients maintained on q12w dosing after loading through Week 52
Zeitfenster: After loading, month 12

This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering treatment naïve patient eyes included in the study.

After loading, month 12
Change in interval length from last interval before switch (baseline) to last interval at end of follow-up (12 months)
Zeitfenster: Baseline, month 12

This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering pre-treated patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eyes.

Baseline, month 12

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Characterize nAMD patients who initiated treatment with brolucizumab with the respect to baseline characteristics
Zeitfenster: Baseline

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Baseline
Evaluate anatomical parameters during treatment with brolucizumab
Zeitfenster: Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Up to month 24
Evaluate VA change from baseline during treatment with brolucizumab
Zeitfenster: Baseline, month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Baseline, month 24
Estimate number of anti-VEGF injections, visits and injection intervals
Zeitfenster: Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Estimate percentage of switchers during first 6 months and characterize switchers
Zeitfenster: Baseline, month 6

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Baseline, month 6
Estimate discontinuation rate and time to discontinuation
Zeitfenster: Month 1-12 and 13-24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Assess retreatment criteria
Zeitfenster: Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Estimate the number of OCT
Zeitfenster: Month 1-12 and 13-24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Assess the safety of brolucizumab
Zeitfenster: Up to month 24

nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Evaluate anatomical effectiveness
Zeitfenster: Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Evaluate treatment intervals
Zeitfenster: Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Describe implementation of treatment schemes into clinical practice
Zeitfenster: Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Evaluate morphological changes under brolucizumab treatment using multimodal imaging
Zeitfenster: Up to month 24

naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Percentage of patient's eyes with absence of IRF and/or SRF at month 12 (naive and switch)
Zeitfenster: Month 12

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 12
Evaluate anatomical parameters during treatment with brolucizumab
Zeitfenster: Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Characterize VA change from baseline during treatment with brolucizumab
Zeitfenster: Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Estimate discontinuation rate during first year of brolucizumab treatment
Zeitfenster: Baseline, month 12

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Baseline, month 12
Estimate time to discontinuation (persistence)
Zeitfenster: Up to month 24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Up to month 24
Estimate the treatment burden
Zeitfenster: Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan

Month 1-12 and 13-24
Estimate the number of OCT and the number of visits with/without OCT
Zeitfenster: Month 1-12 and 13-24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Month 1-12 and 13-24
Assess safety of brolucizumab
Zeitfenster: Up to month 24

DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan.

Up to month 24

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

18. März 2020

Primärer Abschluss (Tatsächlich)

17. November 2025

Studienabschluss (Tatsächlich)

17. November 2025

Studienanmeldedaten

Zuerst eingereicht

4. September 2020

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

4. September 2020

Zuerst gepostet (Tatsächlich)

10. September 2020

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • CRTH258ADE02

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .